Albert Einstein College of Medicine

Vitrisa Therapeutics, Inc.

396419 B.c. Ltd.

Arijit Bhowmick

Matthew Levy

Christopher P Rusconi

Carl Erickson

Kevin G McLure

The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease. In some cases, stem-loop aptamers are provided for the inhibition of Factor D.

Stem-loop compositions and methods for inhibiting factor D

Provided are chemically modified ribonucleic acid (RNA) aptamers comprising one or more of 2'F guanylate, 2&#x2032;OMe cytidylate, 2&#x2032;OMe adenylate, and a deoxy pyrimidine nucleotide with a moiety on the 5 position of the pyrimidine; and methods of making the aptamers.

Chemically modified RNA aptamers and uses thereof

Growing community of inventors

Durham, NC, United States of America

Arijit Bhowmick